Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has voluntarily disclosed the signing of a pharmaceutical contract manufacturing agreement with a European pharmaceutical company valued at approx. KRW 88.4B (USD 63,786,500).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Single Sales and Supply Contract (Voluntary Disclosure)
- Contract Classification & Details: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Details:
- Contract Amount: KRW 88,427,224,950 (USD 63,786,500, applied exchange rate KRW 1,386.30 per USD on August 26, 2025)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on FY2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 1.94%
- Counterparty: Pharmaceutical company based in Europe
- Contract Period: August 26, 2025 – December 31, 2031
- Contract Date: August 26, 2025
- Other Important Details:
- The contract end date is subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure on December 31, 2031, due to business confidentiality, subject to future changes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Execution and Subsequent Official Disclosures
This voluntary disclosure provides notice of a pharmaceutical contract manufacturing deal signed with a European pharmaceutical company valued at approximately KRW 88.4B.
Monitoring potential updates to the contract amount and period, as well as tracking official announcements regarding the counterparty identity upon expiration of the confidentiality period (December 31, 2031), is essential.
Relevant developments can be verified in future correction disclosures, periodic filings, and official disclosures following the confidentiality period.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
